Does CABOZANTINIB Cause Malignant neoplasm progression? 238 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 238 reports of Malignant neoplasm progression have been filed in association with CABOZANTINIB. This represents 6.2% of all adverse event reports for CABOZANTINIB.
238
Reports of Malignant neoplasm progression with CABOZANTINIB
6.2%
of all CABOZANTINIB reports
143
Deaths
132
Hospitalizations
How Dangerous Is Malignant neoplasm progression From CABOZANTINIB?
Of the 238 reports, 143 (60.1%) resulted in death, 132 (55.5%) required hospitalization, and 25 (10.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CABOZANTINIB. However, 238 reports have been filed with the FAERS database.
What Other Side Effects Does CABOZANTINIB Cause?
Diarrhoea (404)
Fatigue (263)
Nausea (215)
Decreased appetite (191)
Off label use (190)
Hypertension (165)
Pyrexia (162)
Vomiting (157)
Asthenia (153)
Death (153)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which CABOZANTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
CABOZANTINIB vs CABOZANTINIB S-MALATE
CABOZANTINIB vs CAFFEINE
CABOZANTINIB vs CALASPARGASE PEGOL
CABOZANTINIB vs CALASPARGASE PEGOL-MKNL
CABOZANTINIB vs CALCIFEDIOL